Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buti

Showing results (521-530 of 1,281) with videos related to

Pageof 129
Sort By:
Gastroenterologia Y Hepatologia|September 9, 2024
Clinical and economic value of bulevirtide in the treatment of chronic hepatitis DMaría Buti, Jose Luis Calleja, Miguel Ángel Rodríguez, et al.
Revista Da Escola De Enfermagem Da U S P|July 14, 2021
Implications of Nursing Care Systematization in Brazilian professional practiceGeorge Luiz Alves Santos, Anderson Reis de Sousa, Nuno Damácio de Carvalho Félix, et al.
Journal of Viral Hepatitis|June 16, 2010
Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up studyM Buti, M Homs, F Rodriguez-Frias, et al.
Archives of Virology. Supplementum|January 1, 1992
Evaluation of anti-HCV positive blood donors identified during routine screeningJ I Esteban, J C Lopez-Talavera, J Genescà, et al.
Gastroenterologia Y Hepatologia|May 16, 2015
[Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice]Javier Crespo, Marina Berenguer, Francisco Pérez, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 14, 2015
Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?Maria Buti, Rosario Casillas, Mar Riveiro-Barciela, et al.
Journal of Viral Hepatitis|November 18, 2014
Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE studyI Dierynck, A Ghys, J Witek, et al.
Current Oncology Reports|July 20, 2025
The Role of Circulating Tumor DNA in Patients Treated with Adjuvant Immune Checkpoint Inhibitors: Clinical Reality or Distant Horizon?Michele Maffezzoli, Ria Nagpal, Mohamed Elewaily, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 21, 2026
Emergency Department Screening Reveals Declining HCV Viraemia but Stable HBV Prevalence in Western Europe: A Sentinel Surveillance OpportunityLena Vargas-Accarino, Murad Ruf, Liam Townsend, et al.
Arxiv|September 26, 2025
Ising energy model for the stochastic prediction of tumor isletsLucas Amoudruz, Gregory Buti, Luciano Rivetti, et al.
Pageof 129

Showing results (521-530 of 1,281) with videos related to

Sort By:
Pageof 129
Gastroenterologia Y Hepatologia|September 9, 2024
Clinical and economic value of bulevirtide in the treatment of chronic hepatitis DMaría Buti, Jose Luis Calleja, Miguel Ángel Rodríguez, et al.
Revista Da Escola De Enfermagem Da U S P|July 14, 2021
Implications of Nursing Care Systematization in Brazilian professional practiceGeorge Luiz Alves Santos, Anderson Reis de Sousa, Nuno Damácio de Carvalho Félix, et al.
Journal of Viral Hepatitis|June 16, 2010
Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up studyM Buti, M Homs, F Rodriguez-Frias, et al.
Archives of Virology. Supplementum|January 1, 1992
Evaluation of anti-HCV positive blood donors identified during routine screeningJ I Esteban, J C Lopez-Talavera, J Genescà, et al.
Gastroenterologia Y Hepatologia|May 16, 2015
[Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice]Javier Crespo, Marina Berenguer, Francisco Pérez, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 14, 2015
Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?Maria Buti, Rosario Casillas, Mar Riveiro-Barciela, et al.
Journal of Viral Hepatitis|November 18, 2014
Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE studyI Dierynck, A Ghys, J Witek, et al.
Current Oncology Reports|July 20, 2025
The Role of Circulating Tumor DNA in Patients Treated with Adjuvant Immune Checkpoint Inhibitors: Clinical Reality or Distant Horizon?Michele Maffezzoli, Ria Nagpal, Mohamed Elewaily, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 21, 2026
Emergency Department Screening Reveals Declining HCV Viraemia but Stable HBV Prevalence in Western Europe: A Sentinel Surveillance OpportunityLena Vargas-Accarino, Murad Ruf, Liam Townsend, et al.
Arxiv|September 26, 2025
Ising energy model for the stochastic prediction of tumor isletsLucas Amoudruz, Gregory Buti, Luciano Rivetti, et al.
Pageof 129